Raltegravir Attenuates Experimental Pulmonary Fibrosis
HMGB1/TLR4/NF-κB
NLRP3 inflammation
NLRP3 inhibitor
Raltegravir
pulmonary fibrosis
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
04
2019
accepted:
18
07
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
5
9
2019
Statut:
epublish
Résumé
Raltegravir, an inhibitor of human immunodeficiency virus-1 (HIV-1) integrase, has been used to treat HIV/acquired immunodeficiency syndrome; however, its therapeutic effects on pulmonary fibrosis have not been investigated. In this study, the
Identifiants
pubmed: 31481891
doi: 10.3389/fphar.2019.00903
pmc: PMC6710384
doi:
Types de publication
Journal Article
Langues
eng
Pagination
903Références
Am J Respir Cell Mol Biol. 2001 May;24(5):591-8
pubmed: 11350829
Am J Respir Crit Care Med. 2002 Feb 1;165(3):406-11
pubmed: 11818329
PLoS Med. 2005 Sep;2(9):e251
pubmed: 16128620
Chest. 2007 Nov;132(5):1652-8
pubmed: 17998366
Am J Respir Cell Mol Biol. 2008 Oct;39(4):440-7
pubmed: 18441281
Drugs. 2009 May 29;69(8):1059-75
pubmed: 19496631
J Immunol. 2009 Aug 1;183(3):2008-15
pubmed: 19587006
J Immunol. 2009 Dec 15;183(12):8244-57
pubmed: 20007588
Am J Physiol Lung Cell Mol Physiol. 2010 Mar;298(3):L348-60
pubmed: 20034962
J Vasc Interv Radiol. 2010 Jun;21(6):896-902
pubmed: 20434368
J Pharmacol Exp Ther. 2010 Aug;334(2):530-9
pubmed: 20472667
AIDS. 2010 Jul 17;24(11):1733-7
pubmed: 20502315
Am J Nephrol. 2010;32(6):590-602
pubmed: 21099216
PLoS One. 2010 Nov 16;5(11):e14003
pubmed: 21103368
J Cardiovasc Pharmacol. 2011 Apr;57(4):376-9
pubmed: 21297493
Pulm Med. 2011;2011:916486
pubmed: 21637372
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
N Engl J Med. 2011 Sep 22;365(12):1079-87
pubmed: 21992121
Eur Respir Rev. 2012 Mar 1;21(123):48-56
pubmed: 22379174
J Gerontol A Biol Sci Med Sci. 2012 Mar;67(3):247-53
pubmed: 22396470
PLoS One. 2013 May 16;8(5):e64373
pubmed: 23696886
Hepatology. 2014 Mar;59(3):898-910
pubmed: 23813842
J Biol Chem. 2014 Aug 1;289(31):21716-26
pubmed: 24939850
Cytokine. 2015 Feb;71(2):223-31
pubmed: 25461402
Toxicol Appl Pharmacol. 2015 Feb 15;283(1):50-6
pubmed: 25582705
Pulm Pharmacol Ther. 2015 Oct;34:1-7
pubmed: 26254990
Cell Mol Immunol. 2016 Mar;13(2):148-59
pubmed: 26549800
Am J Respir Cell Mol Biol. 2016 Aug;55(2):252-63
pubmed: 26933834
Front Pharmacol. 2017 May 30;8:326
pubmed: 28611671
Exp Ther Med. 2017 Aug;14(2):1825-1831
pubmed: 28810656
Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):199-207
pubmed: 28816009
Clin Infect Dis. 2017 Sep 15;65(6):1012-1019
pubmed: 28903510
Nat Rev Drug Discov. 2017 Nov;16(11):755-772
pubmed: 28983101
Toxicol Appl Pharmacol. 2018 Feb 15;341:98-105
pubmed: 29408042
Sci Rep. 2018 Feb 9;8(1):2709
pubmed: 29426911
Front Immunol. 2018 Apr 05;9:670
pubmed: 29675024
Sci Rep. 2018 May 30;8(1):8434
pubmed: 29849053
Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418787991
pubmed: 29993291
Int Immunopharmacol. 2019 Feb;67:458-464
pubmed: 30594776
J Clin Pathol. 1988 Apr;41(4):467-70
pubmed: 3366935